Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

March 28, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Solid Tumor
Interventions
BIOLOGICAL

BNT142

Intravenous bolus/infusion

Trial Locations (18)

19104

University of Pennsylvania, Philadelphia

21201

University of Maryland Medical Center, Baltimore

22031

NEXT Virginia, Fairfax

27705

Duke University Medical Center, Durham

28033

MD Anderson Cancer Center, Madrid

28040

START Madrid-FJD Hospital Universitario Fundacion Jimenez Diaz, Madrid

28041

Hospital Universitario 12 de Octubre - Centro de Actividades Ambulatorias, Madrid

28050

START Madrid CIOCC Hospital Universitario HM Sanchinarro, Madrid

29010

Hospital Universitario Virgen de la Victoria Campus Universitario de Teatinos, Málaga

77030

The University of Texas MD Anderson Cancer Center, Houston

78229

South Texas Accelerated Research Therapeutics (START) - San Antonio, San Antonio

119074

National University Cancer Institute - National University Hospital, Singapore

08023

HM Nou Delfos General Hospital, Barcelona

08035

Hospital Universitario Vall D'Hebron, Barcelona

CB2 0QQ

Cambridge University Hospitals NHS Foundation Trust, Cambridge

L7 8YA

The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool

W12 0HS

Hammersmith Hospital, Imperial College School Of Medicine - Imperial College Healthcare NHS Trust, London

OX3 7LE

Churchill Hospital - Oxford University Hospitals NHS Foundation Trust, Oxford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BioNTech SE

INDUSTRY